Geron (NASDAQ:GERN) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Thursday.
GERN has been the topic of several other reports. Needham & Company LLC reissued a “hold” rating on shares of Geron in a report on Friday, November 3rd. Stifel Nicolaus reissued a “hold” rating and issued a $2.50 target price on shares of Geron in a report on Friday, November 3rd. Finally, Zacks Investment Research raised Geron from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a report on Tuesday, October 3rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. Geron presently has a consensus rating of “Hold” and a consensus price target of $3.75.
Shares of Geron (NASDAQ:GERN) traded up $0.03 on Thursday, hitting $1.94. The stock had a trading volume of 1,062,700 shares, compared to its average volume of 1,650,000. The firm has a market cap of $308.91, a P/E ratio of -10.78 and a beta of 2.59. Geron has a fifty-two week low of $1.74 and a fifty-two week high of $3.15.
Institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp lifted its holdings in Geron by 9.8% during the 2nd quarter. State Street Corp now owns 5,127,578 shares of the biopharmaceutical company’s stock worth $14,205,000 after buying an additional 459,700 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Geron by 783.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 363,990 shares of the biopharmaceutical company’s stock worth $794,000 after buying an additional 322,810 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Geron by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 7,406,968 shares of the biopharmaceutical company’s stock worth $20,518,000 after buying an additional 294,785 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in Geron during the 2nd quarter worth $305,000. Finally, Zacks Investment Management acquired a new position in Geron during the 2nd quarter worth $148,000. 39.21% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Geron (GERN) Upgraded at BidaskClub” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.com-unik.info/2018/01/11/geron-gern-upgraded-at-bidaskclub.html.
Geron Company Profile
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
What are top analysts saying about Geron? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Geron and related companies.